Drug-drug interaction between rifabutin and dolutegravir: A population pharmacokinetic model.
dolutegravir
population pharmacokinetics
rifabutin
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
17
10
2022
received:
12
08
2022
accepted:
05
11
2022
pubmed:
18
11
2022
medline:
17
2
2023
entrez:
17
11
2022
Statut:
ppublish
Résumé
Rifampicin, a potent enzyme inducer, causes marked reduction of dolutegravir exposure. Rifabutin, a less potent enzyme inducer, may offer an alternative to rifampicin. We aimed to characterize the population pharmacokinetics of dolutegravir when co-administered with rifabutin. We extended an existing dolutegravir model to include data from volunteers co-administered with dolutegravir 50 mg and rifabutin 300 mg once daily. We ran simulations of dolutegravir with and without rifabutin co-administration and compare dolutegravir trough concentrations with the IC
Substances chimiques
Rifabutin
1W306TDA6S
Rifampin
VJT6J7R4TR
dolutegravir
DKO1W9H7M1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1216-1221Subventions
Organisme : NIAID NIH HHS
ID : K24 AI150349
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Reese MJ, Savina PM, Generaux GT, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013;41(2):353-361. doi:10.1124/DMD.112.048918
Tshikuka Mulumba JG, Matindii BA, Kilauzi AL, et al. Severity of outcomes associated to types of HIV coinfection with TB and malaria in a setting where the three pandemics overlap. J Community Health. 2012;37(6):1234-1238. doi:10.1007/s10900-012-9559-7
Reinach B, De Sousa G, Dostert P, Ings R, Gugenheim J, Rahmani R. Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes. Chem Biol Interact. 1999;121(1):37-48. doi:10.1016/S0009-2797(99)00089-7
Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003;42(9):819-850. doi:10.2165/00003088-200342090-00003
Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin. J Acquir Immune Defic Syndr. 2013;62(1):21-27. doi:10.1097/QAI.0b013e318276cda9
Modongo C, Wang Q, Dima M, et al. Clinical and virological outcomes of TB/HIV coinfected patients treated with dolutegravir-based HIV antiretroviral regimens. J Acquir Immune Defic Syndr. 2019;82(2):111-115. doi:10.1097/QAI.0000000000002126
Horne DJ, Spitters C, Narita M. Experience with rifabutin replacing rifampin in the treatment of tuberculosis. Int J Tuberc Lung Dis. 2011;15(11):1485-1489. doi:10.5588/ijtld.11.0068
Wang X, Cerrone M, Ferretti F, et al. Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin. Int J Antimicrob Agents. 2019;54(2):202-206. doi:10.1016/j.ijantimicag.2019.04.009
Kawuma AN, Wasmann RE, Dooley KE, Boffito M, Maartens G, Denti P. Population pharmacokinetic model and alternative dosing regimens for dolutegravir coadministered with rifampicin. Antimicrob Agents Chemother. 2022;66(6):e0021522. doi:10.1128/AAC.00215-22
Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol. 2013;2(6):e50. doi:10.1038/psp.2013.24
WHO. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. WHO; 2019.
Cottrell ML, Hadzic T, Kashuba ADM. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 2013;52(11):981-994. doi:10.1007/s40262-013-0093-2
Van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12(2):111-118. doi:10.1016/S1473-3099(11)70290-0
Brainard DM, Kassahun K, Wenning LA, et al. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation. J Clin Pharmacol. 2011;51(6):943-950. doi:10.1177/0091270010375959
Lutz JD, Kirby BJ, Wang L, et al. Cytochrome P450 3A induction predicts P-glycoprotein induction; part 2: prediction of decreased substrate exposure after rifabutin or carbamazepine. Clin Pharmacol Ther. 2018;104(6):1191-1198. doi:10.1002/cpt.1072
Elmeliegy M, Vourvahis M, Guo C, Wang DD. Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug-drug interaction studies. Clin Pharmacokinet. 2020;59(6):699-714. doi:10.1007/s40262-020-00867-1
Grover A, Benet LZ. Effects of drug transporters on volume of distribution. AAPS J. 2009;11(2):250-261. doi:10.1208/S12248-009-9102-7
Ding R, Tayrouz Y, Riedel KD, et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther. 2004;76(1):73-84. doi:10.1016/J.CLPT.2004.02.008
Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RMW, Beijnen JH, Schinkel AH. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol. 2001;59(4):806-813. doi:10.1124/MOL.59.4.806
Schwander S, Rüsch-Gerdes S, Mateega A, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tuber Lung Dis. 1995;76(3):210-218. doi:10.1016/S0962-8479(05)80007-3
Davies GR, Cerri S, Richeldi L. Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev. 2007;2007(4):CD005159. doi:10.1002/14651858.CD005159.pub2
Grassi C, Peona V. Use of rifabutin in the treatment of pulmonary tuberculosis. Clin Infect Dis. 1996;22(Supplement_1):S50-S54. doi:10.1093/clinids/22.supplement_1.s50
Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, et al. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tuber Lung Dis. 1994;75(5):341-347. doi:10.1016/0962-8479(94)90079-5